Blackfynn and Children’s Hospital of Philadelphia (CHOP) announced today that they have expanded their relationship. Under the expanded relationship, Blackfynn’s Data Platform will be used by CHOP and the Children’s Brain Tumor Tissue Consortium (CBTTC) to bring together complex non-identifiable patient data for collaboration and analysis, thereby accelerating translational discovery toward treatments for brain cancer in children.
Blackfynn and CHOP began their relationship focused on pathology data one year ago. The expanded relationship will allow ongoing access to the Blackfynn Data Platform for CHOP and CBTTC members to conduct research across non-identifiable patient data, including pathology, imaging, genomics, EEG, clinical and other data. The ability to integrate and conduct analyses across all relevant data together is crucial to identifying meaningful patterns in treatment and disease.
“We are thrilled to expand our relationship with CHOP, whose commitment to enabling translational research through collaboration and data access inspires us every day,” said Amanda Christini, MD, President of Blackfynn. “We share their core belief that transformational discovery will only occur when experts can effectively use the vast amounts of disparate, complex data generated in research. Blackfynn’s Data Platform will fundamentally enable this goal.”
“The Blackfynn Data Platform will accelerate research by linking experts and non-identifiable data, and will be seamlessly integrated into our CBTTC ecosystem” said Adam Resnick, PhD, CBTTC Scientific Chair. “Our extended relationship with Blackfynn will support the goals of the CBTTC and ultimately could lead to improved outcomes for children with brain tumors.”
About the CBTTC
The CBTTC is a collaborative research program dedicated to improving outcomes for children with brain tumors by supporting research on new prognostic biomarkers and therapies. The CBTTC is composed of thirteen member sites, including CHOP, Stanford, UCSF, Lurie Children’s, Seattle Children’s, University of Pittsburgh Children’s Hospital, Rutgers, Cornell, Children’s National, Hackensack Medical Center, CHOC Children’s, Meyer Children’s and UCSC. The CBTTC informatics infrastructure is supported by the Translational Informatics Unit at CHOP’s Department of Biomedical and Health Informatics (DBHi).
Blackfynn has developed the leading data integration and analysis platform to transform the treatment of neurological diseases. We use our platform and expert team to drive development of disease-modifying therapeutic drugs, enable personalized therapeutic devices and accelerate translational research. Blackfynn has collaborations in place with Marinus Pharmaceuticals, the Epilepsy Study Consortium, the NIH Stimulating Peripheral Activity to Relieve Conditions (SPARC) program, the Children's Hospital of Philadelphia (CHOP), DARPA, NIDA and dozens of academic labs and institutions worldwide. For more information, visit www.blackfynn.com.